NYSE - Nasdaq Real Time Price USD
Edwards Lifesciences Corporation (EW)
90.75 +0.54 (+0.60%)
At close: August 31 at 4:00:03 PM EDT
90.63 -0.12 (-0.13%)
After hours: August 31 at 7:50:58 PM EDT
Trade EW on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for EW
Chart does not reflect overnight price.
What's happening with EW?
Powered by Yahoo ScoutRecent options activity indicates bullish sentiment for Edwards Lifesciences (EW), particularly around the $77.50 put options expiring in November. The company reported strong Q2 results, with revenue growth of 13.6% and reaffirmed its 2026 EPS guidance between $2.95–$3.05.
Powered by Yahoo Scout
- Previous Close
90.21 - Open
91.00 - Bid --
- Ask --
- Day's Range
89.32 - 91.29 - 52 Week Range
72.30 - 96.29 - Volume
4,015,609 - Avg. Volume
4,415,656 - Market Cap (intraday)
52.254B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
53.70 - EPS (TTM)
1.69 - Earnings Date (est.) Oct 29, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
100.96
Recent News
View More
Performance Overview
Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
EW
6.45%
S&P 500 (^GSPC)
12.28%
1-Year Return
EW
11.57%
S&P 500 (^GSPC)
18.98%
3-Year Return
EW
18.67%
S&P 500 (^GSPC)
70.51%
5-Year Return
EW
22.56%
S&P 500 (^GSPC)
69.95%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/27/2026
Market Cap
51.85B
Enterprise Value
48.30B
Trailing P/E
53.54
Forward P/E
29.94
PEG Ratio (5yr expected)
2.16
Price/Sales (ttm)
8.03
Price/Book (mrq)
4.88
Enterprise Value/Revenue
7.42
Enterprise Value/EBITDA
29.23
Financial Highlights
Profitability and Income Statement
Profit Margin
15.43%
Return on Assets (ttm)
8.37%
Return on Equity (ttm)
9.18%
Revenue (ttm)
6.51B
Net Income Avi to Common (ttm)
979.9M
Diluted EPS (ttm)
1.69
Balance Sheet and Cash Flow
Total Cash (mrq)
4.25B
Total Debt/Equity (mrq)
6.57%
Levered Free Cash Flow (ttm)
1.23B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreLifting target to $115, from $105
Edwards Lifesciences designs and manufactures implanted devices to treat advanced cardiovascular diseases. It offers transcatheter-delivered devices to treat aortic stenosis, which is a blockage of the aortic valve due to calcification. It also offers TMTT devices for repair of the mitral and tricuspid valves and solutions for cardiovascular surgery. Edwards was founded in 1958 and is based in Irvine, California. The EW shares are a component of the S&P 500.
RatingPrice TargetThe major indices are lower at midday on Thursday. The Treasury Department
The major indices are lower at midday on Thursday. The Treasury Department jumped in yesterday to support the bond market. That helped yesterday but both the equity and debt markets seem to have reverted back to before the intervention. Crude oil continues to climb again and is at $86 per barrel. The yield on the 10-year note is back up 4 basis points at 4.69%.
Edwards Lifesciences Earnings: Strong Performance Puts Firm on Track to Meet Our 2026 Expectations
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
RatingPrice TargetRiding fast-growing markets
Edwards Lifesciences designs and manufactures implanted devices to treat advanced cardiovascular diseases. It offers transcatheter-delivered devices to treat aortic stenosis, which is a blockage of the aortic valve due to calcification. These devices are marketed under the Edwards SAPIEN family of valves system. Edwards was founded in 1958 and is based in Irvine, California. It has roughly 16,000 employees. The EW shares are a component of the S&P 500.
RatingPrice Target